Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
2.
J Vet Intern Med ; 28(2): 419-28, 2014.
Article in English | MEDLINE | ID: mdl-24765678

ABSTRACT

BACKGROUND: In the dog, the normal estrous cycle includes a prolonged luteal phase. Progesterone stimulates local canine mammary growth hormone (GH) production, which may act systemically and contribute to insulin resistance. Swedish Elkhounds are predisposed to progesterone-related diabetes mellitus, and the relationship among insulin resistance, GH, and insulin-like growth factor I (IGF-I) is of particular interest. OBJECTIVE: To study insulin resistance in relation to GH and IGF-I in nondiabetic Swedish Elkhounds during diestrus. We also assessed whether alterations in these hormones could predict diestrus-linked diseases and all-cause mortality. ANIMALS: Eighty-four privately owned female intact Swedish Elkhounds >4 years of age. METHODS: Blood sampling and clinical examination during luteal phase, with a follow-up questionnaire after 20 months. Insulin resistance was calculated by homeostasis model assessment (HOMA-IR). RESULTS: In multivariable regression analysis, GH was positively associated with HOMA-IR (P = .009). An increase in GH of 1 ng/mL was associated with a 12.7% increase in HOMA-IR. Moreover, C-peptide was positively associated with IGF-I (P = .04), and an increase in C-peptide of 0.1 ng/mL was associated with a 6.9% increase in IGF-I. Structural equation modeling supported these results. Twenty-three animals were found to have previously unrecognized mammary masses and had higher GH (P < .0001) and IGF-I (P = .007) than dogs without mammary masses (n = 61). There was no association between high GH and IGF-I concentrations at sampling and future mammary masses. CONCLUSION: We showed that GH was strongly associated with insulin resistance in older Swedish Elkhounds during diestrus.


Subject(s)
Diestrus/physiology , Dogs/physiology , Growth Hormone/blood , Insulin Resistance/physiology , Insulin-Like Growth Factor I/analysis , Animals , Diestrus/blood , Dog Diseases/etiology , Dog Diseases/physiopathology , Dogs/blood , Female , Growth Hormone/physiology , Insulin-Like Growth Factor I/physiology
3.
Diabetologia ; 51(7): 1135-45, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18496669

ABSTRACT

AIMS/HYPOTHESIS: Insulin-like growth factor-binding protein-1 (IGFBP-1) production in the liver is inhibited by insulin, and low circulating levels are associated with the metabolic syndrome. The aim of this study was to evaluate the predictive role and change in IGFBP-1 concentrations during development of abnormal glucose regulation. METHODS: IGFBP-1 levels were determined at baseline and at 10 years in an incident case-control prospective study of Swedish white men aged 35-56 years. Individuals with normal glucose tolerance at baseline who developed abnormal glucose tolerance during a 10 year period (n = 355) according to WHO criteria were pair-matched to controls for age and family history of diabetes. RESULTS: Fasting IGFBP-1 concentrations were lower in individuals who later developed abnormal glucose regulation and correlated inversely with fasting proinsulin values (r = -0.48; p < 0.0001), and both were significant predictors. Individuals in the highest quartile at baseline for an algorithm incorporating fasting IGFBP-1, blood glucose, proinsulin and waist and height had a 40-fold increased risk of developing type 2 diabetes compared with the lowest quartile (95% CI 7.7-214). IGFBP-1 increased 32% (95% CI 17-49%) during the 10 years in those developing diabetes and was increased in relation to insulin levels, suggesting the emergence of hepatic insulin resistance. Moreover, elevated IGFBP-1 levels at follow-up were associated with higher 2 h glucose values during an OGTT. CONCLUSIONS/INTERPRETATION: Low IGFBP-1 predicts the development of abnormal glucose regulation and, as an inhibitor of the insulin-like actions of insulin-like growth factors, elevated levels of IGFBP-1 after the development of diabetes may also play a pathophysiological role.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/epidemiology , Insulin-Like Growth Factor Binding Protein 1/blood , Adult , Blood Glucose , Body Height , Case-Control Studies , Diabetes Mellitus, Type 2/physiopathology , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Predictive Value of Tests , Proinsulin/blood , Prospective Studies , Risk Factors , Sweden/epidemiology , Waist-Hip Ratio
4.
Horm Res ; 69(2): 99-106, 2008.
Article in English | MEDLINE | ID: mdl-18059090

ABSTRACT

BACKGROUND: The maternal insulin-like growth factor (IGF) system is considered to be involved in fetal growth regulation. However, available data linking this system to fetal growth are contradictory and incomplete. AIMS: To measure components of the IGF system before, during and after pregnancy in healthy women and to relate these results, and their changes during pregnancy, to fetal weight (gestational week 31) and birth weight. METHODS: Serum concentrations of IGF-I, IGF-II, IGF-binding protein (IGFBP)-1, IGFBP-3 and IGFBP-3 protease activity were assessed in 23 women before conception, at weeks 8, 14, 20, 32 and 35 of pregnancy and 2 weeks postpartum. The data were analyzed using simple and multiple linear regression. RESULTS: One third of the variability in fetal weight was explained by IGF-I in combination with IGFBP-3 protease activity, both assessed at gestational week 32 (p = 0.013). Birth weight was negatively correlated (r = -0.43 to -0.59) with IGFBP-1 at gestational week 20 (p = 0.041), 32 (p = 0.012) and 35 (p = 0.003). CONCLUSION: We propose there is a finely tuned balance among the components of the IGF system, providing a means for fetal growth regulation.


Subject(s)
Birth Weight/physiology , Fetal Weight/physiology , Insulin-Like Growth Factor Binding Proteins/blood , Maternal-Fetal Relations , Somatomedins/analysis , Somatomedins/physiology , Adult , Female , Fetal Development/physiology , Gestational Age , Humans , Infant, Newborn , Longitudinal Studies , Mothers , Postpartum Period/blood , Pregnancy/blood
5.
Mol Hum Reprod ; 13(8): 567-76, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17556377

ABSTRACT

Choriocarcinoma is a highly malignant tumor that can arise from trophoblasts of any type of gestational event but most often from complete hydatidiform mole. IGF-II plays a fundamental role in placental development and may play a role in gestational trophoblastic diseases. Several studies have shown that IGF-II is expressed at high levels in hydatidiform moles and choriocarcinoma tissues; however, conflicting data exist on how IGF-II regulates the behaviour of choriocarcinoma cells. The purpose of this study was to determine the contribution of the receptors for IGF-I and insulin to the actions of IGF-II on the regulation of choriocarcinoma cells metastasis. An Immuno Radio Metric Assay was used to analyse the circulating and tissue levels of IGF-I and IGF-II in 24 cases of hydatidiform mole, two cases of choriocarcinoma and eight cases of spontaneous abortion at the same gestational age. The JEG-3 choriocarcinoma cell line was used to investigate the role of IGF-II in the regulation of cell invasion. We found that mole and choriocarcinoma tissue express high levels of IGF-II compared to first trimester placenta. Both IGF-I and IGF-II regulate choriocarcinoma cell invasion in a dose dependent manner but through a different mechanism. IGF-II effects involve the activation of the InsR while IGF-I uses the IGF-IR. The positive effects of IGF-II on invasion are the result of enhanced cell adhesion and chemotaxis (specifically towards collagen IV). The actions of IGF-II but not those of IGF-I were sensitive to inhibition by the insulin receptor inhibitor HNMPA(AM)3. Our results demonstrate that the insulin receptor regulates choriocarcinoma cell invasion.


Subject(s)
Antigens, CD/metabolism , Choriocarcinoma/secondary , Insulin-Like Growth Factor II/physiology , Receptor, Insulin/metabolism , Uterine Neoplasms/pathology , Adult , Cell Adhesion , Cell Line, Tumor , Cell Movement , Choriocarcinoma/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Humans , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/pharmacology , Insulin-Like Growth Factor I/physiology , Insulin-Like Growth Factor II/analysis , Insulin-Like Growth Factor II/pharmacology , Naphthalenes/pharmacology , Organophosphonates/pharmacology , Pregnancy , Proto-Oncogene Proteins c-akt/metabolism , Receptor, IGF Type 1/metabolism , Receptor, Insulin/agonists , Uterine Neoplasms/metabolism
6.
Cell Mol Life Sci ; 63(19-20): 2405-14, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17006628

ABSTRACT

Insulin-like growth factor-binding protein-1 (IGFBP-1) is secreted in a highly phosphorylated form that binds IGF-I with high affinity and is resistant to proteolysis. We have purified IGFBP-1-specific protease activity from the urine of an individual with multiple myeloma. This protease efficiently cleaves both phosphorylated and non-phosphorylated IGFBP-1 at Ile130-Ser131, generating fragments that together have higher association and dissociation rates for IGFs compared with intact IGFBP-1. The proteolytic fraction contained azurocidin, a protease homologue hitherto considered inactive. After cleavage of IGFBP-1, there was a lower affinity, but higher capacity for IGF-I binding, suggesting both N- and C-terminal fragments may interact with ligand independently. There was decreased inhibition of IGF-II-stimulated cell growth and glucose uptake. Alone, proteolysed IGFBP-1 stimulated glucose uptake in muscle. We conclude that specific cleavage of IGFBP-1 at target tissues is important in cellular growth and metabolism and opens novel strategies for targeting IGFBP-1 in treatment of disease.


Subject(s)
Antimicrobial Cationic Peptides/metabolism , Blood Proteins/metabolism , Carrier Proteins/metabolism , Insulin-Like Growth Factor Binding Protein 1/metabolism , Peptide Hydrolases/metabolism , Antimicrobial Cationic Peptides/isolation & purification , Antimicrobial Cationic Peptides/urine , Binding Sites , Blood Proteins/isolation & purification , Blood Proteins/urine , Carrier Proteins/isolation & purification , Carrier Proteins/urine , Cell Line , Chromatography, High Pressure Liquid , Humans , Peptide Hydrolases/isolation & purification , Peptide Hydrolases/urine , Phosphorylation , Protein Isoforms/metabolism , Somatomedins/metabolism
7.
Br J Cancer ; 92(8): 1467-74, 2005 Apr 25.
Article in English | MEDLINE | ID: mdl-15812560

ABSTRACT

Kaposi's sarcoma (KS) is a highly vascular tumour and is the most common neoplasm associated with human immunodeficiency virus (HIV-1) infection. Growth factors, in particular vascular endothelial growth factor (VEGF), have been shown to play an important role in its development. The role of insulin-like growth factors (IGFs) in the pathophysiology of different tumours led us to evaluate the role of IGF system in KS. The IGF-I receptors (IGF-IR) were identified by immunohistochemistry in biopsies taken from patients with different AIDS/HIV-related KS stages and on KSIMM cells (an established KS-derived cell line). Insulin-like growth factor-I is a growth factor for KSIMM cells with a maximum increase of 3H-thymidine incorporation of 130 +/- 27.6% (P < 0.05) similar to that induced by VEGF and with which it is additive (281 +/- 13%) (P < 0.05). Moreover, specific blockade of the receptor (either by alpha IR3 antibody or by picropodophyllin, a recently described selective IGF-IR tyrosine phosphorylation inhibitor) induced KSIMM apoptosis, suggesting that IGF-IR agonists (IGF-I and -II) mediate antiapoptotic signals for these cells. We were able to identify an autocrine loop essential for KSIMM cell survival in which IGF-II is the IGF-IR agonist secreted by the cells. In conclusion, IGF-I pathway inhibition is a promising therapeutical approach for KS tumours.


Subject(s)
Podophyllotoxin/analogs & derivatives , Receptor, IGF Type 1/metabolism , Sarcoma, Kaposi/metabolism , Sarcoma, Kaposi/pathology , Acquired Immunodeficiency Syndrome/complications , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Flow Cytometry , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Podophyllotoxin/pharmacology , Sarcoma, Kaposi/complications , Somatomedins/pharmacology , Vascular Endothelial Growth Factor A/pharmacology
8.
Int J Obes Relat Metab Disord ; 26(10): 1296-300, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12355324

ABSTRACT

OBJECTIVE: Peroxisome-proliferator-activated receptor-alpha (PPARalpha) has a central role in lipid metabolism. Mice lacking PPARalpha accumulate hepatic fat and are prone to late onset obesity. Leptin, an adipocyte-derived hormone, also plays an important role in regulating energy balance. In order to test the hypothesis that leptin secretion increases in response to PPARalpha knockout, we determined leptin concentrations including the effect of nutritional status in male and female PPARalpha knockout mice compared with wild-type controls. DESIGN: We studied the effect of 16 h fasting and 4 h refeeding on plasma leptin concentrations in male and female wild-type and PPARalpha-knockout mice, aged 14 weeks. In female mice the effect of daily growth hormone (GH) injection on the leptin response to refeeding was determined. RESULTS: Circulating leptin concentrations were higher in female mice compared with males and increased in both sexes after PPARalpha-knockout. There was no change in leptin levels after a 16 h fast, compared with ad libitum feeding. However leptin increased with refeeding, to the greatest extent in female PPARalpha-knockout mice. Intermittent GH administration decreased leptin concentrations in female, wild-type and PPARalpha-knockout animals and abolished the exaggerated leptin response to refeeding. CONCLUSIONS: Leptin concentrations are increased in PPARalpha-knockout mice. There are gender differences in the leptin response to feeding which may be due to differences in insulin sensitivity.


Subject(s)
Eating/physiology , Growth Hormone/pharmacology , Leptin/blood , Obesity/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Sex , Transcription Factors/genetics , Animals , Eating/drug effects , Fasting , Female , Insulin/blood , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor I/metabolism , Male , Mice , Mice, Knockout
9.
Growth Horm IGF Res ; 11(5): 303-13, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11735249

ABSTRACT

Peroxisome proliferator-activated receptor alpha (PPARalpha) plays a central role in glucose and lipid homeostasis. Mice lacking PPARalpha(-/-) have a sexually dimorphic phenotype. We have characterized the IGF system in wild type and PPARalpha-/- mice. In normal mice fasting IGF-I and the IGFBP-3 ternary complex were 2-fold higher in males than in females. PPARalpha influenced the IGF/IGFBP response to feeding, particularly in males. Compared to wild type, male PPARalpha-/- mice had 40% lower total fasting IGF-I concentrations, decreased ALS and less IGFBP-3 ternary complex formation, but within 4 h of refeeding there was an increase in IGF-I and IGFBP-3 ternary complex to values similar to controls. Circulating IGFBP protease activity was induced in male PPARalpha-/- mice during refeeding. IGFBP-1 and insulin concentrations were higher in males than females, and were increased by PPARalpha knockout, suggesting significant hepatic insulin resistance. We speculate that gender differences in the IGF system contribute to the PPARalpha-/- phenotype.


Subject(s)
Eating/physiology , Fasting/physiology , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor I/genetics , Receptors, Cytoplasmic and Nuclear/physiology , Transcription Factors/physiology , Animals , Female , Insulin/blood , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 1/isolation & purification , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor Binding Protein 3/isolation & purification , Male , Mice , Mice, Knockout , Nutritional Status , Receptors, Cytoplasmic and Nuclear/deficiency , Receptors, Cytoplasmic and Nuclear/genetics , Sex Characteristics , Transcription Factors/deficiency , Transcription Factors/genetics
10.
J Endocrinol ; 171(3): R11-5, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11739024

ABSTRACT

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates IGF availability for glucose homeostasis. The IGFBP-1 promoter shares common regulatory response elements with phosphoenol pyruvate carboxykinase (PEPCK), the expression and activity of which is inhibited by lithium chloride, associated with an inhibition of glycogen synthase kinase (GSK)-3 activity, in the rat hepatoma cell line H4-II-E. We therefore determined the effect of lithium chloride on IGFBP-1 expression and secretion in H4-II-E cells. Lithium chloride inhibited IGFBP-1 secretion in a dose response and reversible manner by approx 80% during 5-h and 16-h incubations. An inhibitory effect on IGFBP-1 mRNA expression was observed at 2 h. The inhibitory effect of lithium and insulin were not additive when used alone, but inhibition by lithium occurred when insulin action was blocked by activating AMP-activated protein kinase with 5-aminoimidazole-4-carboxamide-riboside (AICAR). These findings suggest that GSK-3 inhibition, or another pathway activated by lithium, may be involved in a pathway controlling IGFBP-1, inhibiting synthesis when insulin activity is absent or impaired.


Subject(s)
Enzyme Inhibitors/pharmacology , Insulin-Like Growth Factor Binding Protein 1/drug effects , Lithium Chloride/pharmacology , Animals , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Glycogen Synthase Kinase 3 , Glycogen Synthase Kinases , Insulin Resistance/physiology , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 1/metabolism , Liver Neoplasms, Experimental/metabolism , RNA, Messenger/genetics , Rats , Tumor Cells, Cultured
11.
Biochem Biophys Res Commun ; 282(5): 1126-31, 2001 Apr 20.
Article in English | MEDLINE | ID: mdl-11302732

ABSTRACT

Insulin-like growth factor-binding protein-1 (IGFBP-1) is stimulated during intensive exercise and in catabolic conditions to very high concentrations, which are not completely explained by known regulators such as insulin and glucocorticoids. The role of AMP-activated protein kinase (AMPK), an important signaling system in lipid and carbohydrate metabolism, in regulating IGFBP-1 was studied in H4-II-E rat hepatoma cells. Arsenic(III) oxide and 5-aminoimidazole-4-carboxamide-riboside (AICAR) were used as activators. AICAR (150 microM) stimulated IGFBP-1 secretion twofold during a 5-h incubation (P = 0.002). Insulin (100 ng/ml) inhibited IGFBP-1 by 80% (P < 0.001), but this was completely abolished in the presence of 150 microM AICAR. The effect of dexamethasone in stimulating IGFBP-1 threefold was additive to the effect of AICAR (P < 0.001) and, in the presence of AICAR, was incompletely inhibited by insulin. In conclusion AMPK is identified as a novel regulatory pathway for IGFBP-1, stimulating secretion and blocking the inhibitory effect of insulin.


Subject(s)
Aminoimidazole Carboxamide/analogs & derivatives , Carcinoma, Hepatocellular/metabolism , Insulin-Like Growth Factor Binding Protein 1/metabolism , Multienzyme Complexes/metabolism , Protein Serine-Threonine Kinases/metabolism , AMP-Activated Protein Kinases , Aminoimidazole Carboxamide/pharmacology , Animals , Arsenic Trioxide , Arsenicals/pharmacology , Culture Media, Conditioned/chemistry , Dexamethasone/antagonists & inhibitors , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Drug Antagonism , Glucocorticoids/antagonists & inhibitors , Glucocorticoids/pharmacology , Insulin/pharmacology , Insulin Antagonists/pharmacology , Insulin-Like Growth Factor Binding Protein 1/analysis , Oxides/pharmacology , Rats , Ribonucleotides/pharmacology , Signal Transduction/drug effects , Tumor Cells, Cultured
12.
Am J Physiol Endocrinol Metab ; 280(4): E650-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11254473

ABSTRACT

Prolonged exercise increases circulating insulin-like growth factor binding protein-1 (IGFBP-1) in humans and animals, but its physiological significance is unknown. This study examined 1) time-course changes in plasma IGFBP-1 and hepatic IGFBP-1 mRNA expression after exercise, 2) changes in IGFBP-1 in relation to plasma glucose, insulin, and IGF-I, and 3) the impact of feeding a postexercise meal on the IGFBP-1 response. Food-deprived male rats were vigorously run on a treadmill and compared with nonexercised controls at 15 min and 1, 4, 8, and 12 h after exercise. Circulating insulin concentrations in exercised rats were lower than in controls at 15 min and 1 h, whereas plasma glucose and IGF-I remained unaffected. Circulating and hepatic expression of IGFBP-1 was markedly increased above that of controls at 15 min, 1 h, and 12 h. In a separate experiment, one-half of the exercised animals received a nutritionally complete meal immediately after the experimental run. The meal elevated plasma insulin and glucose concentrations at 15 min and 1 h. Despite this change in nutritional status, serum IGFBP-1 concentrations and hepatic IGFBP-1 abundance remained elevated at 15 min and 1 h. These results demonstrate that the IGFBP-1 response to a single bout of treadmill exercise is short in duration and independent of insulin, glucose, and amino acid availability.


Subject(s)
Eating/physiology , Insulin-Like Growth Factor Binding Protein 1/blood , Motor Activity/physiology , Animals , Blood Glucose/analysis , Insulin/blood , Insulin-Like Growth Factor Binding Protein 1/metabolism , Insulin-Like Growth Factor I/analysis , Liver/metabolism , Male , Rats , Rats, Sprague-Dawley , Time Factors
13.
J Endocrinol ; 166(1): 21-7, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10856879

ABSTRACT

The 140 kDa ternary complex of insulin-like growth factor-binding protein-3 (IGFBP-3), IGFs and an acid-labile subunit (ALS) has previously been shown to be decreased in diabetes mellitus in humans and rats. We have studied IGF-I levels and ternary complex formation in normal and diabetic cats. Total IGF-I concentrations, measured by RIA using des(1-3)-IGF-I as tracer were (+/-s.e.m.) 54+/-13 nmol/l in eight normal and 227+/-57 nmol/l in eight diabetic cats (P<0.01). The size-distribution of IGFBPs in the cat circulation was determined by incubation with (125)I-IGF-II and Superose 12 chromatography. In normal animals 26+/-2% of the (125)I-IGF-II were in a 140 kDa form compared with 48+/-5% in diabetic cats (P<0.01). When samples from normal and diabetic animals were co-incubated 52+/-3% were at 140 kDa. A similar shift was seen when normal cat and normal human serum were co-incubated. A 2-fold increase in the 140 kDa form in diabetic cats was confirmed first by size-fractionating samples and then performing a ligand-binding assay with (125)I-IGF-I or -II and charcoal separation. SDS-PAGE and Western ligand blotting demonstrated a 45 kDa doublet (presumably IGFBP-3) and 30-35 kDa forms. There were no apparent differences between normal and diabetic profiles on SDS-PAGE, suggesting that a proportion of IGFBP-3 which circulates 'free' in normal cats forms a ternary complex in the diabetic circulation. We conclude that (i) in contrast to humans and rats, ALS is the limiting factor for ternary complex formation in normal cats, (ii) ALS concentrations increase in feline diabetes mellitus and, by promoting ternary complex formation, this leads to an increase in total IGF-I concentrations, and (iii) total IGF-I concentrations may not be reliable in the diagnosis of acromegaly in diabetic cats.


Subject(s)
Acromegaly/veterinary , Cat Diseases/blood , Diabetes Mellitus/blood , Diabetes Mellitus/veterinary , Insulin-Like Growth Factor Binding Protein 3/analysis , Acromegaly/blood , Acromegaly/diagnosis , Animals , Blotting, Western , Carrier Proteins/analysis , Case-Control Studies , Cat Diseases/diagnosis , Cats , Diabetes Mellitus/diagnosis , Electrophoresis, Polyacrylamide Gel , Glycoproteins/analysis , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor II/analysis , Predictive Value of Tests , Radioimmunoassay
14.
Am J Physiol ; 277(4): E693-701, 1999 10.
Article in English | MEDLINE | ID: mdl-10516129

ABSTRACT

Amino acid (AA) levels in plasma and erythrocytes (RBC) were determined in rats (n = 29) fed diets with 6, 21, and 35% protein, and their association with insulin-like growth factor I (IGF-I), insulin, or IGF-binding protein (IGFBP)-1 levels was studied. Free AA in plasma and RBC were determined by reversed-phase high-pressure liquid chromotography, and IGF-I, IGFBP-1, and insulin plasma levels were determined by RIA. Rats fed the low-protein (6%) diet were growth-retarded and had lower serum IGF-I levels and higher serum IGFBP-1 levels than the other two groups (P < 0.0001). In rats fed the low-protein diet, most of the nonessential AA (NEAA) in both plasma and RBC increased, whereas the essential AA (EAA), with the exception of threonine, decreased. When the groups were combined, both RBC and plasma EAA-to-NEAA ratios were positively correlated to IGF-I (r = 0.76 and 0.80, respectively; P < 0.0001) and inversely correlated to IGFBP-1 levels (r = -0.67, P < 0.001 and r = -0.78, P < 0.0001, respectively). A significant inverse correlation was found between RBC glutamate and IGF-I (r = -0.85, P < 0.0001, n = 25) and insulin (r = -0.72, P < 0.001, n = 21), and a positive correlation was found for IGFBP-1 (r = 0.78, P < 0.0001, n = 24). In multiple regression analysis, only IGF-I remained as an independent variable. Threonine was the only EAA with a significant inverse correlation to insulin (r = -0.66, P < 0.001). We hypothesize that AA metabolism is associated to changes in IGF-I, insulin, and IGFBP-1 levels in rats on different protein intakes.


Subject(s)
Amino Acids/blood , Dietary Proteins/pharmacology , Erythrocytes/metabolism , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor I/metabolism , Aging/blood , Animals , Female , Insulin/blood , Rats/genetics , Rats, Sprague-Dawley , Urea/blood
15.
Growth Horm IGF Res ; 9(1): 74-80, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10207511

ABSTRACT

Glucocorticoids usually inhibit growth despite a paradoxical increase in total IGF-I. To investigate the effect of methylprednisolone on free IGF-I, rats were treated with for 3 days (0, 1, 2, 4, and 6 mg/kg per day). A dose-dependent decrease in ultrafiltrated serum free IGF-I was observed, being lowest after 6 mg/kg (P < 0.001 all groups vs controls). Total IGF-I was increased in the groups receiving 2 mg/kg (P < 0.05). Weight change in the 24 h prior to blood sampling was positively correlated with free IGF-I (R = 0.46, P = 0.0002), but not with total IGF-I. Immunoassayable IGFBP-1 was decreased in rats given 4 mg/kg (P = 0.001), whereas there was no change in IGFBP-3 or acid-labile subunit. We propose that in rats the glucocorticoid-induced weight loss may in part be due to suppression of circulating free IGF-I.


Subject(s)
Body Weight/physiology , Insulin-Like Growth Factor I/metabolism , Methylprednisolone/pharmacology , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Body Weight/drug effects , Energy Intake/drug effects , Fasting , Female , Glucocorticoids/administration & dosage , Glucocorticoids/pharmacology , Injections, Subcutaneous , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor I/drug effects , Methylprednisolone/administration & dosage , Rats , Rats, Wistar , Regression Analysis , Ultrafiltration
16.
J Endocrinol ; 159(2): 265-74, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9795367

ABSTRACT

The IGFs are believed to be important in pregnancy and are implicated in the pathophysiology of pre-eclampsia. In adults the IGFs circulate primarily with IGF-binding protein-3 (IGFBP-3) and an acid-labile glycoprotein (ALS) in a 140 kDa complex which limits IGF bioavailability. Less than 10% of IGFBP-3 is in lower molecular weight forms. We have investigated the developmental regulation of the IGF/IGFBP system in normal and pre-eclamptic pregnancies with particular emphasis on the IGFBP-3 ternary complex. Circulating levels of IGF-I, IGFBP-3 and ALS, and their degree of association in the ternary complex in the fetus increased with gestational age. In neonatal serum from deliveries <35 weeks' gestation IGFBP-3 was predominantly in 30-50 kDa form(s) and ALS was a limiting factor for ternary complex formation. In serum from deliveries >35 weeks both ALS and IGFs were limiting but approximately 25% of IGFBP-3 was unable to form the ternary complex even in the presence of excess ALS and IGF-I. Serum IGFBP-1, -2 and -6 concentrations tended to decrease with increasing gestational age. In pre-eclamptic pregnancies, amniotic fluid IGFBP-2, -3 and -6 levels decreased with gestational age while IGFBP-1 levels did not show the normal decline. We speculate that the endocrine IGF system develops in the fetus during the third trimester of pregnancy when ALS levels increase.


Subject(s)
Fetal Blood/chemistry , Insulin-Like Growth Factor Binding Protein 3/metabolism , Pre-Eclampsia/metabolism , Adult , Amniotic Fluid/chemistry , Analysis of Variance , Chromatography, Gel , Female , Gestational Age , Glycoprotein Hormones, alpha Subunit/blood , Humans , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor Binding Protein 2/blood , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor Binding Protein 6/blood , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor II/analysis , Molecular Weight , Pre-Eclampsia/blood , Pregnancy
17.
J Endocrinol ; 158(1): 61-8, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9713327

ABSTRACT

Insulin-like growth factor-binding protein-1 (IGFBP-1) production is increased by somatostatin and its analogues. In order to determine the time course and identify possible mechanisms of this increase in vivo we administered octreotide to rats and determined IGFBP-1 concentrations by RIA. After 60 min of anaesthesia, the mean baseline IGFBP-1 concentrations were 166 (95% confidence interval 123 to 225) ng/ml and increased in saline-infused animals to 729 (488 to 1086) ng/ml after 180 min. IGFBP-1 was stimulated transiently in response to octreotide, with circulating IGFBP-1 concentrations peaking at 1605 (1220 to 2111) ng/ml at 105 min during a continuous infusion of octreotide (100 micrograms/kg per h). In conscious chronically cannulated rats, baseline IGFBP-1 concentrations were 22 (18 to 28) ng/ml, 8-fold less than in the anaesthetised state, and were stimulated in the short term after administration of an octreotide bolus (100 micrograms/kg s.c.) to reach 88 (62 to 126) ng/ml at 60 min. A similar response was seen after i.v. administration to conscious rats. Intravenous bolus of octreotide (100 micrograms/kg) in rats anaesthetised for 3 h resulted in an increase in IGFBP-1 to peak at 1556 (1268 to 1910) ng/ml at 60 min. The IGFBP-1 response to octreotide was diminished in high-fat fed hyperinsulinaemic rats. The pattern of disappearance of iodinated IGFBP-1 from the circulation was not influenced by octreotide. The changes in GH, insulin and glucose concentrations alone did not sufficiently account for the patterns of response observed. We conclude that, in rats, octreotide stimulates IGFBP-1 acutely and this response is potentiated by factors related to anaesthesia.


Subject(s)
Hormones/pharmacology , Insulin-Like Growth Factor Binding Protein 1/blood , Octreotide/pharmacology , Somatostatin/analogs & derivatives , Animals , Blood Glucose/metabolism , Growth Hormone/blood , Insulin/blood , Male , Radioimmunoassay , Rats , Rats, Wistar , Stimulation, Chemical
19.
J Cell Physiol ; 166(1): 121-9, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8557761

ABSTRACT

A sensitive RIA was used to examine regulation of IGFBP-1 in H4IIE rat hepatoma cells. IGFBP-1 was stimulated up to tenfold by dexamethasone and corticosterone, and this stimulation was abolished by RU486. The effect of dexamethasone increased with time in culture. Phorbol 12-myristate 13-acetate (PMA) stimulated IGFBP-1 up to fourfold with a maximal effect in short-term culture. Dexamethasone and PMA were additive in stimulating IGFBP-1. Under basal conditions IGFBP-1 production was linearly related to cell density: however, stimulation by dexamethasone was greatest in confluent cells, and PMA had a greater effect in sparse cultures. Insulin inhibited IGFBP-1 up to 80%, and this effect diminished with time in culture but was unaffected by cell density. Dexamethasone was stimulatory in the presence of a maximal inhibitory concentration of insulin, and insulin was inhibitory in the presence of maximal dexamethasone from 3-48 h in culture, regardless of cell density. PMA abolished the inhibitory action of insulin on IGFBP-1 secretion and mRNA expression during incubation periods of less than 4 h and not during longer incubations. PMA did not influence the stability of IGFBP-1 mRNA. We conclude that, in rat H4IIE cells, dexamethasone and PMA stimulate IGFBP-1 by independent mechanisms and speculate that when protein kinase C is activated the inhibitory action of insulin is blocked.


Subject(s)
Corticosterone/pharmacology , Dexamethasone/pharmacology , Insulin-Like Growth Factor Binding Protein 1/physiology , Insulin/pharmacology , Protein Kinase C/metabolism , Animals , Carcinoma, Hepatocellular , Cell Count , Radioimmunoassay , Rats , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Tumor Cells, Cultured/cytology
20.
Acta Neuropathol ; 91(5): 537-44, 1996.
Article in English | MEDLINE | ID: mdl-8740236

ABSTRACT

Hydranencephaly is defined as the replacement of a previously normal brain, in whole or in part, by membranous fluid-filled sacs. The etiology is not well understood, and the time course of development is unknown. Fifteen ovine fetuses were chronically cannulated and had both carotid arteries ligated at 100 days of gestation (term is 145-150 days). They were killed at 1 (n = 4), 2 (n = 6) and 4 (n = 5) weeks post-surgery, and the findings compared with those of 25 age-matched controls. By 2 weeks post-surgery the entire cerebral hemispheres and diencephalon had been replaced by fluid closely resembling cerebrospinal fluid. The choroid plexus, pituitary and brain stem remained outwardly normal, but the cerebellum showed signs of damage. Fetuses maintained normal values for blood gases and hematocrit up to 4 weeks post-surgery, and grew normally. Light microscopy of the brain stem showed significant losses of cell populations in the medulla by 4 weeks. Vascular casting and acute blood flow studies in an additional group of fetuses showed that the entire brain was perfused via the vertebral-occipital anastomosis immediately after acute bilateral carotid clamping, but that the blood flow rate was insufficient to maintain adequate oxygen delivery.


Subject(s)
Fetal Diseases/pathology , Hydranencephaly/pathology , Animals , Blood Flow Velocity , Brain/blood supply , Brain/pathology , Carotid Stenosis/pathology , Female , Fetal Diseases/etiology , Fetal Diseases/physiopathology , Hydranencephaly/etiology , Hydranencephaly/physiopathology , Ligation , Pregnancy , Sheep
SELECTION OF CITATIONS
SEARCH DETAIL
...